Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

PZ0320

Sigma-Aldrich

PF-04937319

≥98% (HPLC)

Sinônimo(s):

N, N-Dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide, N,N-Dimethyl-5-[[2-methyl-6-[[(5-methyl-2-pyrazinyl)amino]carbonyl]-4-benzofuranyl]oxy]-2-pyrimidinecarboxamide

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C22H20N6O4
Número CAS:
Peso molecular:
432.43
Número MDL:
Código UNSPSC:
51111800
ID de substância PubChem:
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

forma

powder

cor

white to beige

solubilidade

DMSO: 20 mg/mL, clear

temperatura de armazenamento

room temp

cadeia de caracteres SMILES

CC(O1)=CC2=C1C=C(C(NC3=NC=C(C)N=C3)=O)C=C2OC4=CN=C(C(N(C)C)=O)N=C4

InChI

1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)

chave InChI

MASKQITXHVYVFL-UHFFFAOYSA-N

Descrição geral

PF-04937319 is a partial activator of glycokinase (GK) enzyme.

Ações bioquímicas/fisiológicas

PF-04937319 is a glucokinase activator with an EC50 value of 174 nM. PF-04937319 was found to improve glycemic control in adults with type 2 diabetes when used in conjunction with metformin.
PF-04937319, unlike other glucokinase activators, is capable of maintaining lower-glucose levels without it resulting in hypoglycemia. In type II diabetic patients where metformin treatment is inadequate, PF-04937319 is capable of maintaining glycemic control within the acceptable risk-benefit profile.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Raman Sharma et al.
Drug metabolism and disposition: the biological fate of chemicals, 42(11), 1926-1939 (2014-08-22)
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide (PF-04937319), which is under development for the treatment of type 2 diametes mellitus. Metabolic profiling in rat, dog, and human hepatocytes revealed that PF-04937319 is
John C Pettersen et al.
Toxicologic pathology, 42(4), 696-708 (2014-04-29)
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF-04651887, piragliatin, and PF-04937319) was assessed in mice, rats, dogs, and/or monkeys. GKAs were administered for 2 to 8 weeks. Standard
N B Amin et al.
Diabetes, obesity & metabolism, 17(8), 751-759 (2015-04-18)
To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to once-daily PF-04937319 doses of 10

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica